Molecular mechanisms of circulatory dysfunction in cirrhotic portal hypertension

J Chin Med Assoc. 2015 Apr;78(4):195-203. doi: 10.1016/j.jcma.2014.10.004. Epub 2015 Mar 11.

Abstract

Acute or chronic insults to the liver are usually followed by a tissue repairing process. Unfortunately, this action, in most cases, is not effective enough to restore the normal hepatic structure and function. Instead, fibrogenesis and regenerative nodules formation ensue, which are relatively nonfunctioning. The common final stage of the process is liver cirrhosis with increased intrahepatic resistance to portal venous blood flow. Throughout the entire course, the extrahepatic circulatory dysfunction, including increased splanchnic blood flow, elevated portal venous blood flow and pressure, decreased splanchnic and peripheral vascular resistance, tachycardia, and increased cardiac output, are noted and denoted as portal hypertension with hyperdynamic circulatory dysfunction. When such a condition is established, patients may suffer from fatal complications such as gastroesophageal variceal hemorrhage, hepatic encephalopathy, or hepatorenal syndrome. The cause of such a circulatory dysfunction is not fully elucidated. Nevertheless, clarification of the pathophysiology definitely contributes to the control of portal hypertension-related complications. Herein, the molecular mechanism of this intriguing disaster is reviewed and discussed.

Keywords: hyperdynamic circulation; liver cirrhosis; mechanism; portal hypertension.

Publication types

  • Review

MeSH terms

  • Animals
  • Endocannabinoids / physiology
  • Endothelin-1 / physiology
  • Humans
  • Hypertension, Portal / complications
  • Hypertension, Portal / physiopathology*
  • Liver Cirrhosis / complications
  • Liver Cirrhosis / physiopathology*
  • Neuropeptide Y / physiology
  • Portal Vein / physiopathology
  • Splanchnic Circulation
  • Tumor Necrosis Factor-alpha / pharmacology
  • Vascular Endothelial Growth Factor A / physiology
  • Vascular Remodeling

Substances

  • Endocannabinoids
  • Endothelin-1
  • Neuropeptide Y
  • Tumor Necrosis Factor-alpha
  • Vascular Endothelial Growth Factor A